Claims

1) A pharmaceutical composition containing N-acetyl-cysteine and Doxorubicin in amounts effective to show a synergistic effect in the inhibition of cancer metastasis formation.

2) A kit comprising N-acetyl-cysteine and Doxorubicin in amounts sinergistically effective in the inhibition of cancer metastasis formation as well as a medium for the administration thereof.

3) A process for the preparation of a pharmaceutical composition containing N-acetyl-cysteine and Doxorubicin for the inhibition of cancer metastasis formation.

4) A composition according to claim 1 wherein N-acetyl-cysteine is contained in amounts comprised between 100 mg and 6 g.

5) A composition according to claim 1 wherein Doxorubicin is contained in amounts comprised between 1 and 50 mg.

6) A kit according to claim 2 wherein N-acetyl-cysteine is contained in amounts comprised between 100 mg and 6 g.

7) A kit according to claim 2 wherein Doxorubicin is contained in amounts comprised between 1 and 50 mg.

8) A process for the preparation of a pharmaceutical composition according to claim 3 wherein N-acetyl-cysteine is contained in amounts comprised between 100 mg and 6 g.

9) A process for the preparation of a pharmaceutical composition according to claim 3 wherein Doxorubicin is contained in amounts comprised between 1 and 50 mg.

10) A method for inhibiting cancer metastasis formation in a host comprising the aministration to the host of a synergistically effective amount of N-acetyl-cysteine and Doxorubicin.

11) A method for inhibiting cancer metastasis formation in a host according to claim 10 wherein N-acetyl-cysteine is administered in an amount between 100 mg and 6 g/day.

12) A method for inhibiting cancer metastasis formation in a host according to claim 10 wherein Doxorubicin is administered in an amount between 1 and 50 mg per dose.

OR Dox

Add B1